Friday May 3, 2024 | Last Update: May 3, 2024 EDT
Allergan Plc received a subpoena from the U.S. Department of Justice for its Actavis unit, seeking information regarding the marketing and pricing of its generic drugs, according to an article from Bloomberg.
Read more >>
Teva Pharmaceuticals Industries Ltd., a Israeli-based drugmaker, is in advance talks to acquire the generic drugs business of Allergan Plc., according to a report from Bloomberg.
From just being another generics drug maker the past five years, Actavis has earned a spot in one of the Top 10 pharmaceutical companies in the world by market value—thanks to its strategic dealmaking with the $66 billion acquisition of Allergan, Inc.
Actavis is trying its best to finish the deal with Allergan and plans to pay more than $210 per share, or over $62 billion for the pharmaceutical company—higher than their previous offer.
Actavis plans to buy another pharmaceutical company, botox maker Allergan Inc. for at least $60 Billion in order to escape Valeant Pharmaceuticals International Inc.’s hostile offer.
Two Pharmaceutical giants, Salix Pharmaceuticals and Cosmo Pharmaceuticals SpA split up after reportedly terminating their merger agreement due to “changed political environment.”
Allergan Inc Set to Buy Salix Phamaceuticals
Just In
Most Read
1
2
3
4
5